X4 Pharmaceuticals (XFOR) EBITDA (2017 - 2026)
X4 Pharmaceuticals (XFOR) EBITDA from Mar 31, 2017 to Mar 31, 2026. The TTM X4 Pharmaceuticals (XFOR) EBITDA is -$97M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
X4 Pharmaceuticals (XFOR) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +1215.92% |
| 3 Years TTM | +0.56% |
| 5 Years TTM | +7.68% |
| All Time TTM | +20.01% |
Annual EBITDA change of X4 Pharmaceuticals (XFOR)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$20M | -76.54% |
| 2025 | -$86M | +140.48% |
| 2024 | -$36M | -66.76% |
| 2023 | -$107M | +23.02% |
| 2022 | -$87M | +2.90% |
| 2021 | -$85M | +42.15% |
| 2020 | -$60M | +15.35% |
| 2019 | -$52M | +78.05% |
| 2018 | -$29M | +30.66% |
| 2017 | -$22M | -7.81% |
| 2016 | -$24M | N/A |
Comparison X4 Pharmaceuticals (XFOR) five years EBITDA CAGR with competitors
X4 Pharmaceuticals (XFOR) five years EBITDA CAGR is 7.68%.